Gefitinib News and Research

RSS
Gefitinib is approved by the Food and Drug Administration (FDA) to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) that has not gotten better after treatment with other chemotherapy. It is available only as part of a special program called the Iressa Access Program. Gefitinib is also being studied in the treatment of other types of cancer.

Gefitinib is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis.
Erlotinib, gefitinib have similar efficacy in NSCLC patients with EGFR mutation

Erlotinib, gefitinib have similar efficacy in NSCLC patients with EGFR mutation

New era of lung cancer therapy close to dawning

New era of lung cancer therapy close to dawning

Unusual EGFR mutation should influence advanced NSCLC treatment choice

Unusual EGFR mutation should influence advanced NSCLC treatment choice

Lung cancer patients with Del19 mutation benefit most from afatinib

Lung cancer patients with Del19 mutation benefit most from afatinib

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Johns Hopkins researchers use lung cancer drug to shrink chordoma in mice

Johns Hopkins researchers use lung cancer drug to shrink chordoma in mice

Novel multi-kinase inhibitor shows early promise in NSCLC

Novel multi-kinase inhibitor shows early promise in NSCLC

New method to monitor activity of gene promoters during response to drug

New method to monitor activity of gene promoters during response to drug

Icotinib matches gefitinib in NSCLC second or third line

Icotinib matches gefitinib in NSCLC second or third line

Molecular marker predicts longer survival among patients prescribed two cancer drugs

Molecular marker predicts longer survival among patients prescribed two cancer drugs

Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

EGFR mutation testing dropped once funding from pharmaceutical industry discontinued

EGFR mutation testing dropped once funding from pharmaceutical industry discontinued

Seven-year quest to understand how breast cancer cells resist treatment

Seven-year quest to understand how breast cancer cells resist treatment

Researchers find tumors with ALK rearrangements can harbor additional mutations

Researchers find tumors with ALK rearrangements can harbor additional mutations

Review describes current state of lung cancer care

Review describes current state of lung cancer care

Nonfunctional MED12 gene linked to chemotherapy resistance

Nonfunctional MED12 gene linked to chemotherapy resistance

Addition of ficlatuzumab to gefitinib may be effective in select subsets of patients with NSCLC

Addition of ficlatuzumab to gefitinib may be effective in select subsets of patients with NSCLC

New trial data shows improvements in treatment of esophageal and gastrointestinal cancers

New trial data shows improvements in treatment of esophageal and gastrointestinal cancers

Anti-cancer EGFR inhibitors effective in reversing memory loss in animal models of Alzheimer's

Anti-cancer EGFR inhibitors effective in reversing memory loss in animal models of Alzheimer's

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.